Medicenna Therapeutics Corp is facing a downturn, with shares slipping 2.22% in the last trading session.
Investors in Medicenna Therapeutics Corp (MDNA.TO) are feeling the pinch today as the stock closed down 2.22%, settling at CA$0.44. This decline comes amid a lack of significant news that could explain the drop, leaving investors questioning the stock's future prospects.
Investor takeaway: With a market cap of CA$37.5 million and no recent catalysts to boost confidence, investors should be cautious about their positions in Medicenna.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$33.69M
52W high
$1.97
52W low
$0.36
1W change
-6.41%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 776.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+776.7% Upside
Current Price
C$0.36
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
44.4%
Annualized
90-Day Vol
70.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.34 | C$0.30 – C$0.40 |
| 60 trading days | C$0.32 | C$0.26 – C$0.40 |
| 90 trading days | C$0.31 | C$0.23 – C$0.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Medicenna's stock drops 2.22% in one day
The stock's market cap stands at CA$37.5 million, reflecting investor skepticism amid recent offering announcements.
Bull case
If Medicenna can successfully navigate its upcoming public offering and show progress in its clinical trials, it might regain investor confidence and see a rebound.
Bear case
A continued lack of positive news and a struggling market presence could lead to further declines, especially if the public offering fails to attract enough interest.
Market Performance Overview
In the last trading session, Medicenna Therapeutics Corp saw its stock price decrease by 2.22%, closing at CA$0.44. This decline is notable given the company's recent lack of news that could have influenced investor sentiment. With a market cap of CA$37.5 million, the stock's performance is under scrutiny as investors weigh their options.
Lack of Catalysts
Despite recent announcements regarding public offerings, there has been no substantial news to drive the stock price upward. The finalized terms for the public offering, priced at CA$0.50 per unit, may not be enough to instill confidence among investors looking for growth. The absence of positive developments in clinical trials or financial results further exacerbates the situation.
Looking Ahead
As Medicenna navigates its public offering and aims to demonstrate progress in its clinical trials, investors will be closely monitoring the company's next moves. The potential for recovery hinges on the successful execution of these plans and the overall market environment for biotech stocks.
Advertisement
